Business
Air marshaller waving in a plane
(Emmanuele Contini/Getty Images)

The big four US airline stocks have collectively shed about $24 billion in value over the past month

Delta, United, American, and Southwest have all sunk in the past 30 days as tariffs send investors running.

The seatbelt sign hasn’t turned off for a solid month at the big four US airlines.

The market caps of Delta Air Lines, United Airlines, American Airlines, and Southwest Airlines have fallen by roughly $24 billion combined over the past month. Together, the companies control roughly 80% of the US market when accounting for their regional partners.

For context, that’s about the equivalent of losing a Best Buy plus a Mattel, three-ish years of Delta’s Amex credit card income, or roughly 180 737 Max 10s.

Delta, United, and American have dropped by more than 28% each since early February, while Southwest has shed more than 7%. JetBlue, Spirit, and Alaska Air shares are also down significantly.

Sending the oxygen masks down: Trump administration tariffs, which certainly haven’t helped an industry already plagued by accidents this year.

25% levies on steel and aluminum, materials that are key to making things that fly, are set to go into effect on Wednesday. It’s estimated those tariffs could hike the production cost of a narrow-body aircraft by up to $2.5 million. Other duties (delayed or not) have Wall Street fearing a downturn in discretionary spending and travel.

Depending on how long tariffs last, the airline manufacturing supply chain could be in for rough skies. Carriers may lease more jets (as opposed to buying them outright), sending leasing rates higher. Ultimately, that could bump up ticket prices for passengers.

Understandably, the aviation industry isn’t thrilled about the situation. Boeing, which itself is down more than 18% over the past month, could be hit harder than its European rival Airbus due to retaliatory tariffs. The Airbus CEO called the levies a “lose-lose” late last month.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.